Chemoprevention of superficial bladder cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 799-808

  Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemoprevention; Garlic; Green tea; Nonsteroidal anti inflammatory drugs; Pyridoxine; Selenium; Soy; Vitamin A; Vitamin C

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BCG VACCINE; BETA CAROTENE; CARCINOGEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DAIDZEIN; EFLORNITHINE; ETRETINATE; FENRETINIDE; GARLIC EXTRACT; GENISTEIN; GREEN TEA EXTRACT; ISOFLAVONE; ISOTRETINOIN; KETOPROFEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PYRIDOXINE; RETINOIC ACID; RETINOL; SELENIUM; SULINDAC; THIOTEPA; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CHEILITIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONJUNCTIVITIS; DRY SKIN; EATING HABIT; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; NAUSEA; NEPHROTOXICITY; NUTRITION; PROSTATE CANCER; PRURITUS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SUPERFICIAL CANCER; XEROSIS;

EID: 0346958291     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.799     Document Type: Review

References (73)

1. Oliveria SA, Christos PJ, Berwick M. The role of epidemiology in cancer prevention. Proc. Soc. Exp. Biol. Med. 216(2), 142-150 (1997).
2. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol. 127, 250-252 (1982).
3. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 55(2), 161-168 (2000).
4. Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR. Dietary factors and the incidence of cancer of the urinary bladder. Am. J. Epidemiol. 127(6), 1179-1191 (1988).
5. Steineck G, Hagman U, Gerhardsson M, Norell SE. Vitamin A supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985-1987. Int. J. Cancer 45(6), 1006-1011 (1990).
6. Michaud DS, Spiegelman D, Clinton SK et al. Fluid intake and the risk of bladder cancer in men. N. Engl. J. Med 340(18), 1390-1397 (1999).
7. Jones PA, Ross RK. Prevention of bladder cancer. N. Engl J. Med 340(18), 1424-1426 (1999).
8. Geoffroy-Perez B, Cordier S. Fluid consumption and the risk of bladder cancer: results of a multicenter case-control study. Int. J. Cancer 93(6), 880-887 (2001).
9. Rothman N, Talaska G, Hayes RB et al. Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiol. Biomarkers Prev. 6(12), 1039-1042 (1997).
10. Lina BA, van Garderen-Hoetmer A. Effect of urinary pH on the progression of urinary bladder tumours. Food Chem. Toxicol. 37(12), 1159-1166 (1999).
11. Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Urol. Clin. North Am. 19, 629-639 (1992).
12. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim. Biophys. Acta 605, 33-37 (1980).
13. Chomienne C, Ballerini P, Balitrand N et al. All-trans retinoic acid in promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76(9), 1710-1712 (1990).
14. Fenaux P, Degos L. Differentiation therapy for acute promyelocytic leukemia. N. Engl. J. Med. 337(15), 1076-1081 (1997).
15. Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J. Epidemiol. 110(3), 255-263 (1979).
16. Hicks RM. The scientific basis for regarding vitamin A and its analogues as anticarcinogenic agents. Proc. Nutr. Soc. 42(1), 83-86 (1983).
17. Birt DF. Update on the effects of vitamins A, C and E and selenium on carcinogenesis. Proc. Soc. Exp. Biol. Med. 183, 311-320 (1986).
18. Rhodes J, Stokes P, Abrams P. Human tumour-induced inhibition of interferon action in vitro: reversal by beta-carotene (pro-vitamin A). Cancer Immunol. Immunother. 16(3), 189-192 (1984).
19. Moon RC, McCormick DL, Mehta RG. Inhibition of carcinogenesis by retinoids. Cancer Res. 43(5 Suppl.), 2469s (1983).
20. Becci PJ, Thompson HJ, Grubbs CJ, Brown CC, Moon RC. Effect of delay in administration of 13-cis-retinoic acid on the inhibition of urinary bladder carcinogenesis in the rat. Cancer Res. 39(8), 3141-3144 (1979).
21. Miyata Y, Tsuda H, Matayoshi-Miyasato K et al. Effect of vitamin A acetate on urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats. Gann 69(6), 845-848 (1978).
22. Becci PJ, Thompson HJ, Grubbs CJ et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res. 38(12), 4463-4466 (1978).
23. Mathews-Roth MM, Lausen N, Drouin G, Richter A, Krinsky NI. Effects of carotenoid administration on bladder cancer prevention. Oncology 48(3), 177-179 (1991).
24. Dawson WD, Miller WW, Liles WB. Retinyl acetate prophylaxis in cancer of the urinary bladder. Invest. Urol. 16(5), 376 (1979).
25. Pang AS, Morales A . Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and bacillus Calmette Guerin. J. Urol. 130(1), 166-170 (1983).
26. Evard JP, Bollag W. Conservative treatment of recurrent papillomatosis of the urinary bladder with vitamin A. Preliminary report. Schweiz. Med. Wochenschr. 102(51), 1880-1883 (1972).
27. Prout GR Jr, Barton BA. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J. Cell. Biochem. Suppl. 16I, 148(1992).
28. Alfthan O, Tarkkanen J, Grohn P, Heinonen E, Pyrhonen S, Saila K. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur. Urol. 9(1), 6-11 (1983).
29. Studer UE, Jenzer S, Biedermann C et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur. Urol. 28(4), 284-291 (1995).
30. Decensi A, Bruno S, Giaretti W et al. Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate end point. J. Cell. Biochem. 16I, 139 (1992).
31. Decensi A. Torrisi R, Bruno S et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol. Biomarkers Prev. 9(10), 1071-1078 (2000).
32. Albanes D, Heinonen OP, Huttunen JK et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am. J. Clin. Nutr. 62(6 Suppl.), 1427S (1995).
33. Pohl H, Reidy JA. Vitamin C intake influences the bleomycin-induced chromosome damage assay: implications for detection of cancer susceptibility and chromosome breakage syndromes. Mutat. Res. 224(2), 247-251 (1989).
34. Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN. Dietary factors in cancer of the lower urinary tract. Int. J. Cancer 48, 199-121 (1991).
35. Kakizoe T, Takai K, Tobisu K, Ohtani M, Sato S. Validity of short-term examination for antipromoters of bladder carcinogenesis. Jpn. J. Cancer Res. 79, 231-235 (1988).
36. Mirvish SS, Wallcave L, Eagen M, Shubik P. Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. Science 177(43), 65-69 (1972).
37. Mokhtar NM, el-Aaser AA, el-Bolkainy MN, Ibrahim HA, el-Din NB, Moharram NZ. Effect of soybean feeding on experimental carcinogenesis. III. Carcinogenicity of nitrite and dibutylamine in mice: a histopathological study. Eur. J. Cancer Clin. Oncol. 24, 403-407 (1988).
38. Soloway MS, Cohen SM, Dekernion JB, Persky L. Failure of ascorbic acid to inhibit FANFT-induced bladder cancer. J. Urol. 113, 483-489 (1975).
39. Banic S. Vitamin C acts as a co-carcinogen to methylcholanthrene in guinea pigs. Cancer Lett. 11(3), 239-241 (1981).
40. Birt DF. Update on the effects of vitamins A, C and E and selenium on carcinogenesis. Proc. Soc. Exp. Biol. Med. 183, 311-316 (1986).
41. Fukushima S, Ogiso T, Kurata Y, Shibata MA, Kakizoe T. Absence of promotion potential for calcium L-ascorbate, L-ascorbic dipalmitate, L-ascorbic stearate and erythorbic acid on rat urinary bladder carcinogenesis. Cancer Lett. 35, 17-23 (1987).
42. Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M, Ito N. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res. 43, 4454-4461 (1983).
43. Iwata H, Yamamoto S, Yano Y, Ohtani S, Fukushima S. Dose-dependent amplification by L-ascorbic acid of NaHCO3 promotion of rat urinary bladder carcinogenesis. Toxicol. Pathol. 25(3), 284-287 (1997).
44. Kao TL, Meyer WJ III, Post JF. Inhibitory effects of ascorbic acid on growth of leukemic and lymphoma cell lines. Cancer Lett. 70, 101-109 (1993).
45. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br. J. Cancer 66, 673-679 (1992).
46. Brown RR, Price JM, Satter EJ, Wear JB. The metabolism of tryptophan in patients with bladder cancer. Acta Unio Int. Contra Cancrum 16, 299-302 (1960).
47. Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am. J. Clin. Nutr. 46, 659 (1997).
48. Gridley DS, Stickney DR, Nutter RL, Slater JM, Shultz TD. Suppression of tumor growth and enhancement of immune status with high levels of dietary vitamin B6 in BALB/c mice. J. Natl Cancer Inst. 78, 951 (1987).
49. Yoshida O, Brown RR. Bryan GT. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 25, 773-780 (1970).
50. Byar D, Blackard C. Comparisons of placebo, pyridoxine and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10(6), 556 (1977).
51. Newling DW, Robinson MR, Smith PH et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomized Phase III study performed by the EORTC GU Group. Eur. Urol. 27(2), 110 (1995).
52. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 53(5), 1444-1450 (1995).
53. Lamm DL, Riggs DR, Shriver JS, Vanguilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J. Urol. 151, 21 (1994).
54. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol and subsequent bladder cancer. Cancer Res. 49(21), 6144 (1989).
55. Zhou JR, Mukherjee P. Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis and angiogenesis. Cancer Res. 58(22), 5231-5238 (1998).
56. Sun CL, Yuan JM, Arakawa K et al. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol. Biomarkers Prev. 1(12), 1674-1677 (2002).
57. Khan WA, Wang ZY, Athar M, Bickers DR, Mukhtar H. Inhibition of the skin tumorigenicity of (+/-)-7 beta,8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[A]pyrene by tannic acid, green tea polyphenols and quercetin in Sencar mice. Cancer Lett. 42(1-2), 7-12 (1988).
58. Conney AH, Wang ZY, Huang MT, Lou YR, Yang CS. Inhibitory effect of green tea on tumorigenesis by chemicals and ultraviolet light. Prev. Med. 21(3), 361-369 (1992).
59. Sato D, Matsushima M. Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int. J. Urol. 10(3), 160-166 (2003).
60. Lau BHS, Woolley JL, Marsh CL, Barker GR, Koobs DH, Torrey RR. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in the control of murine transitional cell carcinoma. J. Urol. 136, 701-705 (1986).
61. Riggs DR, DeHaven JI, Lamm DL. Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 79, 1987-1994 (1997).
62. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17, 1435-1438 (1996).
63. Okajima E, Ozono S, Endo T, Majima T et al. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jpn. J. Cancer Res. 88, 543-552 (1997).
64. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 169(3), 938-942 (2003).
65. Grubbs CJ, Lubet RA, Koki AT et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60(20), 5599-5602 (2000).
66. Okajima E, Denda A. Ozono S et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 58(14), 3028-3031 (1998).
67. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res. 50(1), 2-9 (1990).
68. Messing EM, Hanson P. Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res. 48 (2), 357-361 (1988).
69. Salim EI, Wanibuchi H, Morimura K et al. Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 21(2), 195-203 (2000).
70. Loprinzi CL, Messing EM, O'Fallon JR et al. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 5(5), 371-378 (1996).
71. Bistrian B. By the way, doctor. I take vitamin E pills but I've heard they can cause bleeding. Is this anything to worry about? Harv. Health Lett. 28(2), 8 (2002).
72. Oh WK, Small EJ. Complementary and alternative therapies in prostate cancer. Semin. Oncol. 29(6), 575-584 (2002).
73. Lachance PA. International perspective: basis, need and application of recommended dietary allowances. Nutr. Rev. 56(4 Pt 2), S2-S4 (1998).